Supplementary file

Table of Contents

Study selection	
Study selection	
Search strategy Error	·! Bookmark not defined
Data retrieval	
Assessment of risk of bias in included studies	
Assessment of heterogeneity and inconsistency of network meta-analysis	
References	
Supplementary Table 1. Full search terms for databases	
Supplementary Table 2. Summary of eligible studies excluded from network meta-analysis due to either no closed loop or data unavailable	
Supplementary Table 3. Summary of the statistical heterogeneity and incoherence for immunogenicity analyses shown in Figure 2	
Supplementary Figure 1. Network of studies included for A) all eligible cohorts, B) immunogenicity analysis cohorts and C) seroefficacy analysis cohorts cohorts and C) seroefficacy analysis cohorts and C) seroefficacy analysis cohorts.	
Supplementary Figure 3. Direct and indirect evidence on geometric mean ratios comparing PCV13 vs PCV10 for serotypes in PCV7 at a) 28 days post	
series, b) pre-booster, and c) 28 days post-booster	2
Supplementary Figure 4. Trial level geometric mean ratios for serotype 4 at post-primary vaccination series	2
Supplementary Figure 5. Trial level geometric mean ratios for serotypes 6B at post-primary vaccination series	2
Supplementary Figure 6. Trial level geometric mean ratios for serotypes 9V at post-primary vaccination series	2
Supplementary Figure 7. Trial level geometric mean ratios for serotypes 14 at post-primary vaccination series.	3
Supplementary Figure 8. Trial level geometric mean ratios for serotypes 18C at post-primary vaccination series	3
Supplementary Figure 9. Trial level geometric mean ratios for serotypes 19F at post-primary vaccination series.	3
Supplementary Figure 10. Trial level geometric mean ratios for serotypes 23F at post-primary vaccination series.	3
Supplementary Figure 11. Trial level geometric mean ratios for serotypes 1 at post-primary vaccination series.	3
Supplementary Figure 12. Trial level geometric mean ratios for serotypes 5 at post-primary vaccination series.	3
Supplementary Figure 13. Trial level geometric mean ratios for serotypes 7F at post-primary vaccination series	3

Supplementary Figure 14. Trial level geometric mean ratios for serotypes 3 at post-primary vaccination series.	37
Supplementary Figure 15. Trial level geometric mean ratios for serotypes 6A at post-primary vaccination series	38
Supplementary Figure 16. Trial level geometric mean ratios for serotypes 19A at post-primary vaccination series	39
Supplementary Figure 17. Trial level geometric mean ratios for serotypes 4 at pre-booster.	40
Supplementary Figure 18. Trial level geometric mean ratios for serotypes 6B at pre-booster.	41
Supplementary Figure 19. Trial level geometric mean ratios for serotypes 9V at pre-booster	42
Supplementary Figure 20. Trial level geometric mean ratios for serotypes 14 at pre-booster.	43
Supplementary Figure 21. Trial level geometric mean ratios for serotypes 18C at pre-booster.	44
Supplementary Figure 22. Trial level geometric mean ratios for serotypes 19F at pre-booster.	45
Supplementary Figure 23. Trial level geometric mean ratios for serotypes 23F at pre-booster.	46
Supplementary Figure 24. Trial level geometric mean ratios for serotypes 1 at pre-booster.	47
Supplementary Figure 25. Trial level geometric mean ratios for serotypes 5 at pre-booster.	48
Supplementary Figure 26. Trial level geometric mean ratios for serotypes 7F at pre-booster.	49
Supplementary Figure 27. Trial level geometric mean ratios for serotypes 3 at pre-booster.	50
Supplementary Figure 28. Trial level geometric mean ratios for serotypes 6A at pre-booster.	51
Supplementary Figure 29. Trial level geometric mean ratios for serotypes 19A at pre-booster.	52
Supplementary Figure 30. Trial level geometric mean ratios for serotypes 4 at post-booster	53
Supplementary Figure 31. Trial level geometric mean ratios for serotypes 6B at post-booster.	54
Supplementary Figure 32. Trial level geometric mean ratios for serotypes 9V at post-booster.	55
Supplementary Figure 33. Trial level geometric mean ratios for serotypes 14 at post-booster	56
Supplementary Figure 34. Trial level geometric mean ratios for serotypes 18C at post-booster	57
Supplementary Figure 35. Trial level geometric mean ratios for serotypes 19F at post-booster	58
Supplementary Figure 36. Trial level geometric mean ratios for serotypes 23F at post-booster	59
Supplementary Figure 37. Trial level geometric mean ratios for serotypes 1 at post-booster	60
Supplementary Figure 38. Trial level geometric mean ratios for serotypes 5 at post-booster	61
Supplementary Figure 39. Trial level geometric mean ratios for serotypes 7F at post-booster	62
Supplementary Figure 40. Trial level geometric mean ratios for serotypes 3 at post-booster	63
Supplementary Figure 41. Trial level geometric mean ratios for serotypes 6A at post-booster.	
Supplementary Figure 42. Trial level geometric mean ratios for serotypes 19A at post-booster.	65
Supplementary Figure 43. Sensitivity analysis on geometric mean ratios comparing PCV13 vs PCV10, PCV7 vs PCV10, and PCV13 vs PCV7 at a) post-primary vaccination	
series, b) pre-boost, and c) post-boost by including studies providing data for all three time points	
Supplementary Figure 44. Direct and indirect evidence on relative risk comparing PCV13 vs PCV10 for serotypes in PCV7 (4, 6B, 9V, 14, 18C, 19F and 23F)	69
Supplementary Figure 45. Trial level relative risk for serotype 4.	70
Supplementary Figure 46. Trial level relative risk for serotype 6B	71

Supplementary Figure 47. Trial level relative risk for serotype 9V	72
Supplementary Figure 48. Trial level relative risk for serotype 14	73
Supplementary Figure 49. Trial level relative risk for serotype 18C	74
Supplementary Figure 50. Trial level relative risk for serotype 4	75
Supplementary Figure 51. Trial level relative risk for serotype 23F	76
Supplementary Figure 52. Trial level relative risk for serotype 1	77
Supplementary Figure 53. Trial level relative risk for serotype 5	78
Supplementary Figure 54. Trial level relative risk for serotype 7F	79
Supplementary Figure 55. Study level association between geometric mean ratio and relative risk for each serotype in PCV7	80

Methods

Our systematic review protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews). Registration number: CRD42019124580.

Search strategy

The search strategy was devised and conducted by an information specialist (NR). Five databases and two trial registers were searched from database inception to 27th July 2022. The original search was run in June 2019, with an update search run in July 2022. The databases searched were Cochrane Database of Systematic Reviews & Cochrane Central Register of Controlled Trials (Cochrane Library, Wiley)[Issue 7 of 12, July 2022], Embase (OvidSP)[1974-present], Global Health (OvidSP)[1973 to 2022 Week 29] and Medline (OvidSP)[1946-present]. The trial registers searched were ClinicalTrials.gov (https://clinicaltrials.gov/) and WHO International Clinical Trials Registry Platform (https://trialsearch.who.int/). The search comprised of title/abstract keywords and subject headings for pneumococcal vaccines and children. A methodological search filter for randomised controlled trials taken from the Cochrane Handbook was used to limit to RCTs. 1.2 Pharmaceutical company websites (GSK and Pfizer) were also hand searched for relevant studies. A full list of search terms for each database is summarised in Supplementary Table 1. No date or language limits were applied. References were exported to Endnote 20 for de-duplication.

Study selection

Two reviewers (JM, NP) independently reviewed the title and abstract of each reference and identified potentially relevant references. Two reviewers (JM, NP) independently selected studies to be included in the review from retrieved full-text papers using predetermined inclusion criteria. Disagreements about study inclusion were resolved by a third reviewer (MV).

Randomised controlled trials were included if they provided head-to-head comparisons of either PCV7, PCV10, or PCV13 among infants and children less than 2 years of age, and if they provided estimates on antibody responses (serotype-specific anti-pneumococcal IgG) to PCVs for at least one time point of 1) between 4 and 6 weeks after the primary vaccination series, and/or one-month after a booster vaccination. Trials were eligible only if they included at least one of the three currently licensed (PCV10 and 13) or previously licensed (PCV7) vaccines.

Trials were excluded if they did not contain a head-to-head randomised comparison of eligible vaccines, contained only a single vaccine, or enrolled immuno-compromised (e.g. HIV) children.

PCVs in systematic review

- 7-valent pneumococcal conjugate vaccine (PCV7: Prevnar, Pfizer), containing serotypes 4, 6B, 9V, 14, 18C,
 19F, and 23F, each conjugated to diphtheria cross-reacting material (CRM).
- 13-valent pneumococcal conjugate vaccine (PCV13: Prevenar 13, Pfizer), containing serotypes 1, 3, 4, 5, 6A,
 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, each conjugated to diphtheria cross-reacting material (CRM).
- 10-valent pneumococcal conjugate vaccine (PCV10: Synflorix, GlaxoSmithKline), containing serotypes 1, 4, 5,
 6B, 7F, 9V, 14, 18C, 19F, and 23F, conjugated to non-typeable Haemophilus influenzae protein D, for 8 serotypes, or tetanus or diphtheria protein (serotypes 18C and 19F respectively).

Data retrieval

For all eligible trials, the publication authors/data owners were approached for trial and individual participant level data. Baseline characteristics and potential effect modifiers were extracted on participants' age, sex, country, immunogenicity assays, co-administered study vaccines and vaccine schedules. The following study-level data were extracted from trial registries/published studies:

- trial registration number/study identifier
- study country
- PCV vaccination schedule (e.g. 2+1, 3+1, 3+0)

Individual participant level data were retrieved if available for variables below.

 vaccines administered (both study vaccines and vaccines administered concomitantly as part of the routine immunisation schedule)

- vaccination dates
- details of laboratory assays conducted, including where assays were run, units of measurement,
 and the lower limit of quantification
- participants' age at enrolment
- participants' sex
- serotype-specific anti-pneumococcal IgG measured by ELISA at all time-points

Aggregate data from publications were extracted if individual participant data were not available. Data extraction of published results and individual participant level data were independently completed by SF and MV.

Assessment of risk of bias in included studies

Risk of bias in results of the included studies was assessed independently by two reviewers (JM, NP) using the Cochrane Risk of Bias Tool (RoB 2).³ This considers the risk of bias in five domains (randomisation process, deviations from the intended interventions, missing outcome data, measurement of the outcome, selection of the reported result) and generates an overall risk of bias. Assessments were undertaken for immunogenicity of PCV7, PCV10 and PCV13 for each serotype contained in the vaccines. Risks of bias for sero-efficacy outcomes are assumed to be identical because the data came from the same blood samples and were analysed in similar ways. The possible risk of bias judgments for each domain, and overall, are 'low risk of bias', 'some concerns' and 'high risk of bias'.

Disagreements between reviewers were resolved by consensus. Results for the risk of bias assessment were presented using robvis (visualisation tool).⁴

Assessment of heterogeneity and inconsistency of network meta-analysis

To assess the statistical heterogeneity and inconsistency of NMA, we evaluated the transitivity assumption by visually comparing the distribution of the baseline characteristics and potential effect modifiers across the different pairwise comparisons. We assessed the presence of heterogeneity using estimated values of the heterogeneity variance parameters (τ 2) and the I-squared statistic and its 95% confidence interval that measures the percentage of variability in point estimates that cannot be attributed to random error. We evaluated the inconsistency, i.e. coherence between direct and indirect evidence, using a Q statistic, which measures the deviation from

consistency. The random-effects model was fitted following the graph-theoretical approach and using the GMR and RR as effect estimate with 95% CI.⁶

Some individual participant level data were missing due to laboratory errors, insufficient blood sample volume or participant withdrawal. Data were not imputed and missing data were considered missing-completely-at-random. Individual participant level data were analysed according to the vaccine received.

References

- 1. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, Noel-Storr A, Rader T, Shokraneh F, Thomas J, Wieland LS. Technical Supplement to Chapter 4: Searching for and selecting studies.
- 2. Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from: www.training.cochrane.org/handbook.
- 3. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *Bmj* 2019; **366**: 14898.
- 4. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods* 2021; **12**(1): 55-61.
- 5. Schwarzer G, Carpenter JR, Rücker G. Network Meta-Analysis. Meta-Analysis with R. Cham: Springer International Publishing; 2015: 187-216.
- 6. Rücker G. Network meta-analysis, electrical networks and graph theory. *Res Synth Methods* 2012; **3**(4): 312-24.
- 7. A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine. Available from: https://clinicaltrials.gov/ct2/show/NCT00169481. Last accessed on 09 Nov 2022.
- 8. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. *Journal of Infectious Diseases* 1996; **174**(6): 1271-8.
- 9. Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. *Vaccine* 2018; **36**(45): 6883-91.
- 10. Rupp R, Hurley D, Grayson S, et al. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. *Human vaccines & Immunotherapeutics* 2019; **15**(3): 549-59.
- 11. Thisyakorn U, Chokephaibulkit K, Kosalaraksa P, Benjaponpitak S, Pancharoen C, Chuenkitmongkol S. Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine. *Human vaccines & Immunotherapeutics* 2014; **10**(7): 1859-65.
- 12. Martinez CPD, Linares-Perez N, Toledo-Romani ME, et al. Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I. *Vaccine* 2018; **36**(32 Pt B): 4944-51.
- 13. Platt HL, Greenberg D, Tapiero B, et al. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. *Pediatr Infect Dis J* 2020; **39**(8): 763-70.
- 14. Bili A, Dobson S, Quinones J, et al. A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13TM with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION). *Open Forum Infectious Diseases* 2021; **8**(SUPPL 1): S684.
- 15. Shin J, Teeratakulpisarn J, Puthanakit T, et al. Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: A randomized double-blind active-controlled trial. *Korean Journal of Pediatrics* 2020; **63**(7): 265-71.

- 16. Chen JJ, Yuan L, Huang Z, et al. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China. *BMJ Open* 2016; **6**(10): e012488.
- 17. Zhao Y, Li G, Xia S, et al. Immunogenicity and Safety of a Novel 13-Valent Pneumococcal Vaccine in Healthy Chinese Infants and Toddlers. *Front Microbiol* 2022; **13**: 870973.
- 18. Senders S, Klein NP, Lamberth E, et al. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. *Pediatr Infect Dis J* 2021; **40**(10): 944-51.
- 19. Senders S, Klein NP, Lamberth E, et al. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States. *Open Forum Infectious Diseases* 2020; **7**(SUPPL 1): S637.
- 20. Banniettis N, Wysocki J, Szenborn L, et al. Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU-PLAN). *Open Forum Infectious Diseases* 2021; **8**(SUPPL 1): S678.
- 21. Martinon-Torres F, Gimenez-Sanchez F, Gurtman A, et al. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. *Pediatric Infectious Disease Journal* 2012; **31**(4): 392-9.
- 22. Vanderkooi OG, Scheifele DW, Girgenti D, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. *Pediatric Infectious Disease Journal* 2012; **31**(1): 72-7.
- 23. De Los Santos AM, Rodriguez-Weber MA, Sanchez-Marquez P, et al. Immunogenicity of a 2 + 1 infant vaccination series with 13-valent pneumococcal conjugate vaccine (PCV13) followed by pneumococcal non-typeable haemophilus influenzae protein d conjugate vaccine (PHID-CV): A randomized trial exploring interchangeability of PCVS. *Open Forum Infectious Diseases* 2017; **4 (Supplement 1)**: S538-S9.
- 24. Diez-Domingo J, Gurtman A, Bernaola E, et al. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain. *Vaccine* 2013; **31**(46): 5486-94.
- 25. Clarke E, Bashorun AO, Okoye M, et al. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial. *Vaccine* 2020; **38**(2): 399-410.
- 26. Clarke E, Bashorun A, Adigweme I, et al. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* 2021; **21**(6): 834-46.

Supplementary Table 1. Full search terms for databases.

placebo.ab.

Medline (Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE®) 1946 to present Streptococcus pneumoniae/ (pneumococc* or s pneumoniae or strep* pneumoniae or strep* p).ti,ab. 1 or 2 vaccines/ or bacterial vaccines/ or streptococcal vaccines/ or Vaccines, Conjugate/ (vaccin* or immuni?ation? or immuni?e? or inoculat* or conjugate).ti. (conjugate adj2 vaccin*).ti,ab. (7 valent or 7valent or seven valent or heptavalent or hepta-valent).ti,ab. (9 valent or 9valent or nine valent or nonavalent or nona-valent).ti,ab. (10 valent or 10valent or ten valent or decavalent or deca-valent).ti,ab. (13 valent or 13valent or thirteen valent).ti,ab. 4 or 5 or 6 or 7 or 8 or 9 or 10 3 and 11 exp Pneumococcal Vaccines/ ((pneumococc* or s pneumoniae or strep* pneumoniae or strep* p) adj5 (vaccin* or immuni?ation? or immuni?e? or inoculat* or conjugate)).ti,ab. (pcv7 or pcv 7 or pncrm* or pnccrm* or 7vpnc or 7vcrm).ti,ab. (pcv9 or pcv 9).ti,ab. (pcv10 or pcv 10 or phidcv or phid cv).ti,ab. (pcv13 or pcv 13 or 13vcrm).ti,ab. (pneumovax or pneumopur or streptopur or streptorix or prevnar or prevenar or synflorix or gsk 1024850a or gsk1024850a).ti,ab. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 exp child/ or infant/ (child* or infan* or baby or babies or toddler? or preschool* or pre-school* or p?ediatric?).ti,ab. 21 or 22 20 and 23 randomized controlled trial.pt. controlled clinical trial.pt. randomized.ab.

drug therapy.fs.

randomly.ab.

trial.ab.

groups.ab.

25 or 26 or 27 or 28 or 29 or 30 or 31 or 32

exp animals/ not humans.sh.

33 not 34

24 and 35

limit 24 to ("reviews (maximizes specificity)" or "systematic review")

36 or 37

(2019* or 2020* or 2021* or 2022*).ed,ez,yr.

38 and 39

Embase 1974 to present

Streptococcus pneumoniae/

(pneumococc* or s pneumoniae or strep* pneumoniae or strep* p).ti,ab.

1 or 2

vaccine/ or bacterial vaccine/ or streptococcus vaccine/

(vaccin* or immuni?ation? or immuni?e? or inoculat* or conjugate).ti.

(conjugate adj2 vaccin*).ti,ab.

(7 valent or 7valent or seven valent or heptavalent or hepta-valent).ti,ab.

(9 valent or 9valent or nine valent or nonavalent or nona-valent).ti,ab.

(10 valent or 10valent or ten valent or decavalent or deca-valent).ti,ab.

(13 valent or 13valent or thirteen valent).ti,ab.

4 or 5 or 6 or 7 or 8 or 9 or 10

3 and 11

pneumococcus vaccine/

((pneumococc* or s pneumoniae or strep* pneumoniae or strep* p) adj5 (vaccin* or immuni?ation? or immuni?e? or inoculat* or conjugate)).ti,ab.

(pcv7 or pcv 7 or pncrm* or pnccrm* or 7vpnc or 7vcrm).ti,ab.

(pcv9 or pcv 9).ti,ab.

(pcv10 or pcv 10 or phidcv or phid cv).ti,ab.

(pcv13 or pcv 13 or 13vcrm).ti,ab.

(pneumovax or pneumopur or streptopur or streptorix or prevnar or prevenar or synflorix or gsk 1024850a or gsk1024850a).ti,ab. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19

exp child/

(child* or infan* or baby or babies or toddler? or preschool* or pre-school* or p?ediatric?).ti,ab.

21 or 22

20 and 23

randomized controlled trial/

single blind procedure/ or double blind procedure/

crossover procedure/

random*.tw.

(((singl* or doubl*) adj (blind* or mask*)) or crossover or cross over or factorial* or latin square or assign* or allocat* or volunteer*).ti,ab.

25 or 26 or 27 or 28 or 29

(exp animals/ or nonhuman/) not human/

30 not 31

24 and 32

limit 24 to ("systematic review" or "reviews (maximizes specificity)")

33 or 34

(2019* or 2020* or 2021* or 2022*).yr,dd,dc.

35 and 36

Global Health <1973 to 2022 Week 29>

streptococcus pneumoniae/

(pneumococc* or s pneumoniae or strep* pneumoniae or strep* p).ti,ab.

1 or 2

vaccines/ or conjugate vaccines/

(vaccin* or immuni?ation? or immuni?e? or inoculat* or conjugate).ti.

(conjugate adj2 vaccin*).ti,ab.

(7 valent or 7valent or seven valent or heptavalent or hepta-valent).ti,ab.

(9 valent or 9valent or nine valent or nonavalent or nona-valent).ti,ab.

(10 valent or 10valent or ten valent or decavalent or deca-valent).ti,ab.

(13 valent or 13valent or thirteen valent).ti,ab.

4 or 5 or 6 or 7 or 8 or 9 or 10

3 and 11

((pneumococc* or s pneumoniae or strep* pneumoniae or strep* p) adj5 (vaccin* or immuni?ation? or immuni?e? or inoculat* or conjugate)).ti,ab.

(pcv7 or pcv 7 or pncrm* or pnccrm* or 7vpnc or 7vcrm).ti,ab.

(pcv9 or pcv 9).ti,ab.

(pcv10 or pcv 10 or phidcv or phid cv).ti,ab.

(pcv13 or pcv 13 or 13vcrm).ti,ab.

(pneumovax or pneumopur or streptopur or streptorix or prevnar or prevenar or synflorix or gsk 1024850a or gsk1024850a).ti,ab.

12 or 13 or 14 or 15 or 16 or 17 or 18

exp children/ or infants/

(child* or infan* or baby or babies or toddler? or preschool* or pre-school* or p?ediatric?).ti,ab.

20 or 21

19 and 22

(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*).mp.

23 and 24

(2019* or 2020* or 2021* or 2022*).yr.

25 and 26

ClinicalTrials.gov - 1/6/2019

(pneumococcal OR pneumococcus OR "streptococcus pneumoniae" OR "streptococcal pneumoniae" OR "streptococcus p" OR "streptococcal p") AND (vaccine OR vaccines OR vaccination OR immunisation OR immunisation OR immunisation OR incolate) | Child

(pneumococcal OR pneumococcus OR "streptococcus pneumoniae" OR "streptococcal pneumoniae" OR "streptococcus p" OR "sterptococcal p") AND (conjugate OR valent) | Child

pcv7 or pcv 7 or pncrm or pnccrm or 7vpnc or 7vcrm or pcv9 or pcv 9 or pcv10 or pcv 10 or phidcv or phid cv or pcv13 or pcv 13 or 13vcrm

 $pneumovax\ or\ pneumopur\ or\ streptopur\ or\ streptorix\ or\ prevnar\ or\ prevenar\ or\ synflorix\ or\ gsk\ 1024850a\ or\ gsk\ 1024850a\ |\ Child\ or\ prevenar\ or\ gsk\ pre$

ClinicalTrials.gov - 2022 - Added since 01/06/2019

Other terms=(pneumococcal OR pneumococcus OR "streptococcus pneumoniae" OR "streptococcal pneumoniae" OR "streptococcus p" OR "streptococcal p") AND (vaccine OR vaccines OR vaccination OR immunisation OR im

Title=(pneumococcal OR pneumococcus OR "streptococcus pneumoniae" OR "streptococcal pneumoniae" OR "streptococcus p" OR "streptococcal p") AND (vaccine OR vaccines OR vaccination OR immunisation OR immunisation OR immunisation OR immunisation OR inoculate) | Child | First posted from 06/01/2019 to 01/01/2024

Condition=(pneumococcal OR pneumococcus OR "streptococcus pneumoniae" OR "streptococcal pneumoniae" OR "streptococcus p" OR "streptococcal p") AND Intervention=(vaccine OR vaccines OR vaccination OR immunisation OR immunisation OR immunisation OR immunisation OR inoculate) | Child |
First posted from 06/01/2019 to 01/01/2024

Other terms=(pneumococcal OR pneumococcus OR "streptococcus pneumoniae" OR "streptococcal pneumoniae" OR "streptococcus pneumoniae" OR "streptococcal pneumoniae" OR "streptococcus pneumo

Title=(pneumococcal OR pneumococcus OR "streptococcus pneumoniae" OR "streptococcal pneumoniae" OR "streptococcus p" OR "streptococcus

Condition=(pneumococcal OR pneumococcus OR "streptococcus pneumoniae" OR "streptococcal pneumoniae" OR "streptococcus p" OR "streptococcus pneumoniae" OR "streptococcus p" OR "streptococcus pneumoniae" OR "streptococcus pneumoniae" OR "streptococcus pneumoniae" OR "streptococcus pneumoniae" OR "streptococcus p" OR "streptococcus pneumoniae" OR "streptococcus pneumoni

Other terms=pcv7 or pcv 7 or pncrm or pnccrm or 7vpnc or 7vcrm or pcv9 or pcv 9 or pcv10 or pcv 10 or phidcv or phid cv or pcv13 or pcv 13 or 13vcrm | Child

Title=pcv7 or pcv 7 or pncrm or pnccrm or 7vpnc or 7vcrm or pcv9 or pcv 9 or pcv10 or pcv 10 or phidcv or phid cv or pcv13 or pcv 13 or 13vcrm | Child Intervention=pcv7 or pcv 7 or pncrm or pnccrm or 7vpnc or 7vcrm or pcv9 or pcv 9 or pcv10 or pcv 10 or phidcv or phid cv or pcv13 or pcv 13 or 13vcrm | Child

Other terms=pneumovax or pneumopur or streptopur or streptorix or prevnar or prevenar or synflorix or gsk 1024850a or gsk1024850a | Child

Title=pneumovax or pneumopur or streptopur or streptorix or prevnar or prevenar or synflorix or gsk 1024850a or gsk1024850a | Child

Intervention=pneumovax or pneumopur or streptopur or streptorix or prevnar or prevenar or synflorix or gsk 1024850a or | Child

WHO ICTRP

pneumococcal vaccine OR pneumococcus vaccine OR pneumococcal conjugate OR pneumococcus conjugate OR pcv OR pneumovax OR pneumopur OR streptopur OR streptorix OR prevnar OR prevnar OR synflorix OR gsk 1024850a - TRIALS IN CHILDREN

Cochrane (CDSR - limited to Publication date: 01/06/2019-27/07/2022, CENTRAL - limited to Added to database date: 01/06/2019-27/07/2022)

ID	Search
#1	MeSH descriptor: [Streptococcus pneumoniae] explode all trees
#2	(pneumococc* or "s pneumoniae" or "streptococcus pneumoniae" or "streptococcus p" or "streptococcal pneumoniae" or "streptococcal p")
#3	#1 or #2
#4	MeSH descriptor: [Vaccines] this term only
#5	MeSH descriptor: [Bacterial Vaccines] this term only
#6	((vaccin* or immunization* or immunize* or immunisation* or immunise* or inoculat* or conjugate or valent)):ti,ab,kw
#7	#4 or #5 or #6
#8	#3 and #7
#9	MeSH descriptor: [Pneumococcal Vaccines] explode all trees

#10	((pcv7 or "pcv 7" or pncrm* or pnccrm* or 7vpnc or 7vcrm)):ti,ab,kw
#11	((pcv9 or "pcv 9")):ti,ab,kw
#12	(pcv10 or" pcv 10" or phidcv or "phid cv"):ti,ab,kw
#13	(pcv13 or "pcv 13" or 13vcrm):ti,ab,kw
#14	pneumovax or pneumopur or streptopur or streptorix or prevnar or prevenar or synflorix or gsk 1024850a or gsk1024850a
#15	#8 or #9 or #10 or #11 or #13 or #14
#16	MeSH descriptor: [Child] explode all trees
#17	MeSH descriptor: [Infant] this term only
#18	(child* or infan* or baby or babies or toddler* or preschool* or pre-school* or pediatric* or paediatric*):ti,ab,kw
#19	#16 or #17 or #18
#20	#15 and #19

Supplementary Table 2. Summary of eligible studies excluded from network meta-analysis due to either no closed loop or data unavailable.

	Author & Year*	NCT	Comparison	
	Trial register ⁷	NCT00169481	pcv7 vs pcv11	
	Dagan et al. 19968	Not found	pcv7 vs ppv23	
	Greenberg et al. 2018 ⁹	NCT01215188	pcv13 vs pcv15	
	Dumm at al. 201010	NCT0251373	n av 12 va n av 15	
	Rupp et al. 2019 ¹⁰	NCT02037984	pcv13 vs pcv15	
	Thisyakorn et al. 2014 ¹¹	NCT00594347	pcv7 vs ppv23	
	Martinez et al. 2018 ¹²	RPCE00000173	Cuban pcv7 vs pcv10	
Studies with	Platt et al. 2020 ¹³	NCT02987972	pcv15 vs pcv13	
no closed loop	Bili et al. 2021 ¹⁴	NCT03620162	pcv15 vs pcv13	
	Shin et al. 2020 ¹⁵	NCTR20170109002	pcv12 vs pcv13	
	Chen et al. 2016 ¹⁶ ;	NCT02726240	7 - Chi 12	
	Zhao et al. 2022 ¹⁷	NCT02736240	pcv7 vs Chinese pcv13	
	Senders et al. 202118;	NGT02512200	12 20	
	Senders et al. 202019	NCT03512288	pcv13 vs pcv20	
	Banniettis et al. 2021 ²⁰	NCT03885934	pcv15 vs pcv13	
Studies with	Martinon-Torres et al.	N. C. T. O.	T 40	
data	2012 ²¹	NCT00474539	pcv7 vs pcv13	
unavailable	Vanderkooi et al. 2012 ²²	NCT00475033	pcv7 vs pcv13	
	De Los Santos et al. 2017 ²³	NCT01641133	pcv10 vs pcv13	
	Diez-Domingo et al. 2013 ²⁴	NCT00368966	pcv7 vs pcv13	
	Clarke et al. 2020 ^{25*}	NCT02308540	pcv10-SII vs pcv13	
	Clarke et al. 2021 ^{26*}	NCT03197376	pcv10 vs pcv10-SII	

^{*} Individual participant data unavailable

PCV – Pneumococcal conjugate vaccine; PPSV - Pneumococcal polysaccharide vaccine; PCV10-SII – 10-valent Pneumococcal conjugate vaccine by Serum Institute of India

Supplementary Table 3. Summary of the statistical heterogeneity and incoherence for immunogenicity analyses shown in Figure 2

Serotype	Time point	No. of study	prop study	lo. and portion of providing t evidence	No. of participants providing direct evidence	No. of participants providing indirect evidence	tau	l² (%)	p-value (Q of heterogene ity and inconsiste ncy; df)	p-value (Q of heterogene ity; df)	p-value (Q of inconsiste ncy; df)
4	post prime	28	9	47.9%	2,356	9,258	0.089	86.8 (82.0-90.4)	0.000 (197.440;26)	0.000 (196.733;25)	0.400 (0.707;1)
6B	post prime	28	9	59.7%	2,356	9,194	0.109	82.2 (75.0-87.3)	0.000 (145.913;26)	0.000 (108.043;25)	0.000 (37.870;1)
9V	post prime	28	9	48.0%	2,360	9,241	0.078	83.8 (77.5-88.4)	0.000 (160.708;26)	0.000 (158.678;25)	0.154 (2.030;1)
14	post prime	28	9	48.6%	2,358	9,186	0.069	71.1 (57.4-80.4)	0.000 (89.983;26)	0.000 (83.435;25)	0.010 (6.548;1)
18C	post prime	28	9	50.9%	2,358	9,258	0.147	93.7 (91.9-95.1)	0.000 (413.924;26)	0.000 (405.782;25)	0.004 (8.142;1)
19F	post prime	28	9	51.8%	2,358	9,235	0.199	96.2 (95.3-96.9)	0.000 (679.122;26)	0.000 (675.147;25)	0.046 (3.975;1)
23F	post prime	28	9	55.1%	2,358	9,211	0.095	80.6 (72.5-86.3)	0.000 (133.979;26)	0.000 (131.123;25)	0.091 (2.856;1)
1	post prime	9	9	100%	2,357		0.177	93.8 (90.4-96.1)	0.000 (130.029;8)		
5	post prime	9	9	100%	2,356		0.193	95.1 (92.5-96.7)	0.000 (161.837;8)		
7F	post prime	9	9	100%	2,358		0.056	63.6 (25.3-82.3)	0.005 (21.980;8)		

3	post prime	9	9	100%	2,354		0.495	99.2 (99.0-99.4)	0.000 (1006.362;8)		
6A	post prime	9	9	100%	2,354		0.514	99.0 (98.8-99.2)	0.000 (825.778;8)		
19A	post prime	9	9	100%	2,356		0.381	98.1 (97.5-98.6)	0.000 (428.259;8)		
4	prior booster	17	7	68.9%	1,816	4,174	0.098	83.7 (74.8-89.4)	0.000 (92.071;15)	0.000 (90.267;14)	0.179 (1.805;1)
6B	prior booster	17	7	74.3%	1,812	4,140	0.141	87.7 (81.7-91.8)	0.000 (122.370;15)	0.000 (112.127;14)	0.001 (10.242;1)
9V	prior booster	17	7	68.1%	1,810	4,175	0.112	88.3 (82.6-92.1)	0.000 (127.983;15)	0.000 (127.962;14)	0.885 (0.021;1)
14	prior booster	17	7	64.9%	1,816	4,178	0.044	39.5 (0-66.6)	0.053 (24.789;15)	0.045 (24.090;14)	0.403 (0.699;1)
18C	prior booster	17	7	65.6%	1,806	4,177	0.089	82.0 (71.8-88.5)	0.000 (83.259;15)	0.000 (68.689;14)	0.000 (14.571;1)
19F	prior booster	17	7	78.9%	1,807	4,151	0.128	84.2 (75.6-89.7)	0.000 (94.673;15)	0.000 (69.142;14)	0.000 (25.531;1)
23F	prior booster	17	7	72.9%	1,808	4,170	0.104	79.0 (66.5-86.8)	0.000 (71.375;15)	0.000 (68.632;14)	0.098 (2.742;1)
1	prior booster	7	7	100%	1,820		0.121	87.9 (77.5-93.5)	0.000 (49.663;6)		
5	prior booster	7	7	100%	1,813		0.090	80.3 (59.9-90.3)	0.000 (30.418;6)		
7F	prior booster	7	7	100%	1,812		0.075	73.7 (43.6-87.7)	0.001 (22.787;6)		

3	prior booster	7	7	100%	1,813		0.236	95.0 (91.8-96.9)	0.000 (119.248;6)		
6A	prior booster	7	7	100%	1,805		0.191	93.2 (88.4-96.0)	0.000 (87.690;6)		
19A	prior booster	7	7	100%	1,811		0.115	79.2 (57.2-89.8)	0.000 (28.782;6)		
4	post booster	25	6	53.1%	1,706	8,457	0.063	72.9 (59.3-81.9)	0.000 (84.813;23)	0.000 (75.091;22)	0.002 (9.722;1)
6B	post booster	25	6	53.1%	1,707	8,434	0.088	80.1 (71.1-86.3)	0.000 (115.374;23)	0.000 (100.081;22)	0.000 (15.293;1)
9V	post booster	25	6	52.2%	1,706	8,457	0.078	83.0 (75.8-88.1)	0.000 (135.599;23)	0.000 (134.490;22)	0.292 (1.108;1)
14	post booster	25	6	46.8%	1,705	8,446	0.063	71.9 (57.7-81.3)	0.000 (81.916;23)	0.000 (81.857;22)	0.808 (0.059;1)
18C	post booster	25	6	54.0%	1,705	8,453	0.074	79.6 (70.3-86.0)	0.000 (112.643;23)	0.000 (112.118;22)	0.469 (0.525;1)
19F	post booster	25	6	53.8%	1,707	8,443	0.113	87.9 (83.2-91.2)	0.000 (189.802;23)	0.000 (186.331;22)	0.062 (3.471;1)
23F	post booster	25	6	59.1%	1,705	8,437	0.080	75.9 (64.4-83.7)	0.000 (95.591;23)	0.000 (95.039;22)	0.457 (0.552;1)
1	post booster	6	6	100%	1,705		0.045	48.7 (0-79.6)	0.083 (9.739;5)		
5	post booster	6	6	100%	1,706		0.101	83.9 (66.4-92.3)	0.000 (31.010;5)		
7F	post booster	6	6	100%	1,705		0.044	57.4 (0-82.8)	0.039 (11.732;5)		

3	post booster	6	6	100%	1,701	0.299	96.9 (95.2-98.0)	0.000 (162.413;5)
6A	post booster	6	6	100%	1,704	0.239	94.1 (89.8-96.6)	0.000 (85.221;5)
19A	post booster	6	6	100%	1,705	0.158	87.1 (74.2-93.5)	0.000 (38.745;5)

df: degree of freedom; tau: square-root of between-study variance; l²: heterogeneity statistic; Q of heterogeneity and inconsistency: overall heterogeneity/inconsistency statistic. Q of heterogeneity: overall heterogeneity statistic. Q of inconsistency: overall inconsistency statistic.


Supplementary Table 4. Summary on assessment of statistical heterogeneity and incoherence for seroefficacy analysis shown in Figure 3

Serotype	No. of study	No. and proporti study p direct e	ion of roviding	No. of participants providing direct evidence	No. of participants providing indirect evidence	tau	l² (%)	p-value (Q of heterogene ity and inconsiste ncy; df)	p-value (Q of heterogene ity; df)	p-value (Q of inconsiste ncy; df)
4	15	6	89.0%	1,577	3,531	0.383	23.7 (0-59.5)	0.198 (17.036;13)	0.178 (16.286;12)	0.386 (0.750;1)
6B	15	6	91.6%	1,573	3,466	0.249	74.4 (56.7-84.9)	0.000 (50.756;13)	0.000 (48.136;12)	0.105 (2.621;1)
9V	15	6	90.7%	1,574	3,518	0.309	43.0 (0-69.6)	0.044 (22.801;13)	0.049 (21.065;12)	0.188 (1.736;1)
14	15	6	81.3%	1,578	3,524	0.361	69.6 (47.4-82.5)	0.000 (42.834;13)	0.000 (40.642;12)	0.139 (2.192;1)
18C	15	6	95.1%	1,568	3,537	0.474	49.9 (7.4-72.9)	0.017 (25.961;13)	0.017 (24.657;12)	0.254 (1.304;1)
19F	15	6	80.2%	1,569	3,497	0.327	49.1 (5.7-72.5)	0.020 (25.541;13)	0.104 (18.415;12)	0.008 (7.126;1)
23F	15	6	93.6%	1,570	3,498	0.557	83.8 (74.3-89.9)	0.000 (80.480;13)	0.000 (78.982;12)	0.221 (1.498;1)
1	6	6	100%	1,581		0.403	42.7 (0-77.3)	0.121 (8.724;5)		
5	6	6	100%	1,573		0.975	82.2 (62.1-91.6)	0.000 (28.031;5)		
7F	6	6	100%	1,575		0.000	0 (0-74.6)	0.537 (4.084;5)		

3	6	6	100%	1,571	0.580	67.4 (22.7-86.3)	0.009 (15.356;5)
6A	6	6	100%	1,564	0.735	96.1 (93.6-97.6)	0.000 (127.663;5)
19A	6	6	100%	1,571	0.836	91.4 (84.0-95.3)	0.000 (57.901;5)

df: degree of freedom; tau: square-root of between-study variance; l²: heterogeneity statistic; Q of heterogeneity and inconsistency: overall heterogeneity/inconsistency statistic. Q of heterogeneity: overall heterogeneity statistic. Q of inconsistency: overall inconsistency statistic.

Supplementary Figure 1. Network of studies included for A) all eligible cohorts, B) immunogenicity analysis cohorts and C) seroefficacy analysis cohorts



PCV – Pneumococcal conjugate vaccine; PPSV - Pneumococcal polysaccharide vaccine; PCV10-SII – 10-valent Pneumococcal conjugate vaccine by Serum Institute of India; PCV7 Cuba – a Cuban PCV7; PCV13 CNY – a Chinese PCV13

Supplementary Figure 2. Assessment of risk of bias for included studies

	Risk of bias domains						
	D1	D2	D3	D4	D5	Overall	
Bermal 2009	<u> </u>	+	+	<u>+</u>	<u>+</u>		
Kim 2011	<u>-</u>	<u> </u>	+	+	+	<u>-</u>	
Knuf 2012	<u>-</u>	<u>-</u>	+	+	+	<u>-</u>	
Prymula 2017	+	+	+	+	+	+	
Carmona Martinez 2019	+	<u> </u>	+	+	+	<u>-</u>	
Temple 2019	+	<u>-</u>	+	+	+	<u>-</u>	
van den Bergh 2011	+	<u>-</u>	+	+	+	<u>-</u>	
Vesikari 2009	+	<u>-</u>	+	+	+	<u>-</u>	
Wysocki 2009	<u>-</u>	<u>-</u>	X	+	+	X	
Amedaker 2013	<u>-</u>	+	+	-	+	<u>-</u>	
Dagan 2013	<u>-</u>	<u>-</u>	+	+	<u>-</u>	<u>-</u>	
Esposito 2010	+	+	+	+	+	+	
Grimprel 2011	+	+	+	+	+	+	
Huang 2012	<u>-</u>	+	+	+	+	<u>-</u>	
Kieninger 2010	+	+	+	+	+	+	
Kim 2013	+	<u>+</u>	+	+	+	+	
Payton 2013	+	+	+	+	+	+	
Pomat 2018	+	<u>-</u>	+	+	<u>-</u>	<u>-</u>	
Snape 2010	+	+	+	+	+	+	
Togashi 2015	<u>-</u>	+	+	+	+	<u>-</u>	
Weckx 2012	+	+	+	+	+	+	
Yeh 2010	+	+	+	+	+	+	
Zhu 2016	+	+	+	+	+	+	
Bryant 2010	+	X	+	+	<u>-</u>	X	
Odutola 2017	+	<u>-</u>	+	+	-	<u>-</u>	
Leach 2021	+	<u>-</u>	+	+	+	<u>-</u>	
Madhi 2020	<u>-</u>	-	+	+	+	<u>-</u>	

- Domains:
 D1: Bias arising from the randomization process.
 D2: Bias due to deviations from intended intervention.
 D3: Bias due to missing outcome data.
 D4: Bias in measurement of the outcome.
 D5: Bias in selection of the reported result.


Judgement

🚺 High


Some concerns


🕕 Low

Supplementary Figure 3. Direct and indirect evidence on geometric mean ratios comparing PCV13 vs PCV10 for serotypes in PCV7 at a) 28 days post-primary vaccination series, b) pre-booster, and c) 28 days post-booster



a)






GMR: Geometric mean ratio; PCV: Pneumococcal conjugate vaccine. Each line in the figure shows the output from a network meta-analyses. Dark grey diamonds and lines show the point estimates and confidence intervals for geometric mean ratios from studies directly comparing PCV13 vs PCV10. Light grey diamonds and lines show the point estimates and confidence intervals for geometric mean ratios from studies comparing PCV13 vs PCV10 through PCV7. Black boxes and lines show the point estimates and confidence intervals incorporating both direct and indirect evidence.

Supplementary Figure 4. Trial level geometric mean ratios for serotype 4 at post-primary vaccination series.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 4 - post prime	GMR (95%CI)
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV	!=-	1.13 (0.95-1.33)
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV	-=-	1.29 (1.10-1.50)
2	pcv7 vs pcv10	Asia	2-4-6 months	Hib-TT	-■	1.31 (1.12-1.54)
3	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		1.81 (1.39-2.36)
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	1.52 (1.32-1.76)
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	1.94 (1.78-2.12)
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-TT/IPV + MenC		1.50 (1.30-1.71)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	 -	1.38 (1.10-1.73)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT) 	1.66 (1.42-1.94)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		1.50 (1.31-1.73)
18	pcv13 vs pcv10	Oceania	1-2-3 months	DTPw-HBV-Hib-TT + OPV	∔= —	1.14 (0.91-1.43)
25	pcv13 vs pcv10	Africa	2-3-4 months	DTPw-HBV-Hib-TT + OPV		1.67 (1.41-1.97)
26	pcv13 vs pcv10	Oceania	2-4-6 months	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	1.27 (1.02-1.59)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.60 (0.42-0.86)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.53 (0.36-0.77)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-■ 	0.76 (0.55-1.05)
10	pcv13 vs pcv7	Asia	6-10-14 weeks	DTwP-Hib-HBV+OPV		0.85 (0.72-1.00)
11	pcv13 vs pcv7	Asia	2-4-6 months	NA	-	1.07 (0.99-1.15)
14	pcv13 vs pcv7	Asia	2-4-6 months	DTPa-(HBV)-Hib-TT/IPV	-	0.62 (0.50-0.78)
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	-	0.73 (0.64-0.84)
16	pcv13 vs pcv7	Asia	2-4-6 months	DTPa-HBV-Hib-TT/IPV	-=-	0.79 (0.64-0.98)
17	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV	=	0.76 (0.68-0.86)
19	pcv13 vs pcv7	Europe	2-4 months	DTaP-IPV-Hib/MenC	-	0.53 (0.36-0.78)
20	pcv13 vs pcv7	Asia	enr 3-6 m, 4-8 w int	DTPa	-	0.81 (0.71-0.93)
21	pcv13 vs pcv7	South America	2-4-6 months	HBV-DTwP-Hib/OPV/Rotavirus	-	0.75 (0.65-0.87)
22	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV	-	0.67 (0.58-0.76)
23	pcv13 vs pcv7	Asia	3-4-5 months	NA	-	0.78 (0.70-0.87)
24	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV	-	0.72 (0.57-0.91)
					- 	
					0.0 0.5 1.0 1.5 2.0 2.5	
				1	favours vac2 GMR(lgG) favours vac	1

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 5. Trial level geometric mean ratios for serotypes 6B at post-primary vaccination series.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 6. Trial level geometric mean ratios for serotypes 9V at post-primary vaccination series.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 9V - post prime	GMR (95%CI)
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV	!	1.24 (1.03-1.49)
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV		1.71 (1.44-2.04)
2	pcv7 vs pcv10	Asia	2-4-6 months	Hib-TT		1.47 (1.23-1.76)
3	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	─	• 2.37 (1.78-3.16)
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	1.47 (1.27-1.70)
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	2.09 (1.91-2.29)
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-TT/IPV + MenC	_=_	1.85 (1.59-2.16)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	 = -	1.19 (0.96-1.48)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT) 	1.57 (1.36-1.82)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		2.00 (1.72-2.33)
18	pcv13 vs pcv10	Oceania	1-2-3 months	DTPw-HBV-Hib-TT + OPV	 	1.19 (0.95-1.49)
25	pcv13 vs pcv10	Africa	2-3-4 months	DTPw-HBV-Hib-TT + OPV	-	1.23 (1.00-1.52)
26	pcv13 vs pcv10	Oceania	2-4-6 months	DTPa-HBV-Hib-TT/IPV/Rotavirus		1.55 (1.26-1.92)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.56 (0.41-0.75)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		0.88 (0.60-1.29)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	- ■ 	0.88 (0.61-1.28)
10	pcv13 vs pcv7	Asia	6-10-14 weeks	DTwP-Hib-HBV+OPV	- = -	0.92 (0.79-1.08)
11	pcv13 vs pcv7	Asia	2-4-6 months	NA	÷	0.98 (0.91-1.05)
14	pcv13 vs pcv7	Asia	2-4-6 months	DTPa-(HBV)-Hib-TT/IPV	-	0.67 (0.56-0.82)
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	-	0.83 (0.73-0.94)
16	pcv13 vs pcv7	Asia	2-4-6 months	DTPa-HBV-Hib-TT/IPV	-= 1	0.89 (0.74-1.08)
17	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV	=	0.81 (0.74-0.90)
19	pcv13 vs pcv7	Europe	2-4 months	DTaP-IPV-Hib/MenC	-	0.62 (0.41-0.93)
20	pcv13 vs pcv7	Asia	enr 3-6 m, 4-8 w int	DTPa	-	0.74 (0.64-0.86)
21	pcv13 vs pcv7	South America	2-4-6 months	HBV-DTwP-Hib/OPV/Rotavirus	=	0.87 (0.75-1.01)
22	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV	-	0.70 (0.61-0.80)
23	pcv13 vs pcv7	Asia	3-4-5 months	NA	-	0.77 (0.70-0.85)
24	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV	-	0.81 (0.66-0.99)
					0.0 0.5 1.0 1.5 2.0 2.5	
				f	favours vac2 GMR(IgG) favours vac1	I


GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 7. Trial level geometric mean ratios for serotypes 14 at post-primary vaccination series.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 8. Trial level geometric mean ratios for serotypes 18C at post-primary vaccination series.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 9. Trial level geometric mean ratios for serotypes 19F at post-primary vaccination series.



GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 10. Trial level geometric mean ratios for serotypes 23F at post-primary vaccination series.



GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 11. Trial level geometric mean ratios for serotypes 1 at post-primary vaccination series.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 1 - post prime	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		1.49 (1.20-1.86)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT	- - -	1.62 (1.39-1.88)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		2.21 (1.89-2.57)
18	pcv13 vs pcv10	Oceania	1-2-3 months	DTPw-HBV-Hib-TT + OPV	+- -	1.15 (0.93-1.42)
25	pcv13 vs pcv10	Africa	2-3-4 months	DTPw-HBV-Hib-TT + OPV		1.63 (1.37-1.93)
26	pcv13 vs pcv10	Oceania	2-4-6 months	DTPa-HBV-Hib-TT/IPV/Rotavirus		1.81 (1.47-2.24)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.37 (0.27-0.51)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.82 (0.61-1.11)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	1.04 (0.81-1.34)
					<u> </u>	
					0.0 0.5 1.0 1.5 2.0 2.5	
				1	favours vac2 GMR(lgG) favours vac1	

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 12. Trial level geometric mean ratios for serotypes 5 at post-primary vaccination series.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 5 - post prime	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	-	1.23 (0.97-1.56)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT	- - -	1.30 (1.12-1.51)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		1.88 (1.66-2.13)
18	pcv13 vs pcv10	Oceania	1-2-3 months	DTPw-HBV-Hib-TT + OPV	+	1.01 (0.85-1.20)
25	pcv13 vs pcv10	Africa	2-3-4 months	DTPw-HBV-Hib-TT + OPV		1.32 (1.10-1.59)
26	pcv13 vs pcv10	Oceania	2-4-6 months	DTPa-HBV-Hib-TT/IPV/Rotavirus	— 	2.49 (2.01-3.08)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.36 (0.25-0.50)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.53 (0.37-0.75)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.94 (0.71-1.24)
					0.0 0.5 1.0 1.5 2.0 2.5	
				1	favours vac2 GMR(lgG) favours vac	

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 13. Trial level geometric mean ratios for serotypes 7F at post-primary vaccination series.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 7F - po	ost prime	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV			1.37 (1.12-1.67)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)	-8	1.44 (1.26-1.64)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		-=-	1.60 (1.42-1.82)
18	pcv13 vs pcv10	Oceania	1-2-3 months	DTPw-HBV-Hib-TT + OPV		-■	1.29 (1.08-1.55)
25	pcv13 vs pcv10	Africa	2-3-4 months	DTPw-HBV-Hib-TT + OPV		-■	1.29 (1.09-1.53)
26	pcv13 vs pcv10	Oceania	2-4-6 months	DTPa-HBV-Hib-TT/IPV/Rotavirus		■	1.72 (1.41-2.10)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		<u>-</u>	0.75 (0.52-1.09)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	-	1.18 (0.83-1.67)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus			1.37 (1.02-1.84)
					0.0 0.5 1.	0 1.5 2.0 2.5	
				1	favours vac2 GMR	(lgG) favours vac1	

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 14. Trial level geometric mean ratios for serotypes 3 at post-primary vaccination series.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 3 - post prime	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		43.33 (33.78-55.58)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)	44.21 (38.12-51.27)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		15.16 (13.17-17.46)
18	pcv13 vs pcv10	Oceania	1-2-3 months	DTPw-HBV-Hib-TT + OPV		2.19 (1.72-2.78)
25	pcv13 vs pcv10	Africa	2-3-4 months	DTPw-HBV-Hib-TT + OPV		90.36 (72.44-112.73)
26	pcv13 vs pcv10	Oceania	2-4-6 months	DTPa-HBV-Hib-TT/IPV/Rotavirus		5.60 (4.55-6.90)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		4.84 (3.92-5.99)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		11.99 (9.53-15.10)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		7.50 (5.88-9.57)
				,	0.0 0.5 1.0 1.5 2.0 2.5 favours vac2 GMR(lgG) favours vac	1

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 15. Trial level geometric mean ratios for serotypes 6A at post-primary vaccination series.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 6A - post prime	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		18.67 (14.07-24.76)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)	17.14 (13.99-20.99)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		6.19 (5.21-7.36)
18	pcv13 vs pcv10	Oceania	1-2-3 months	DTPw-HBV-Hib-TT + OPV	→	3.54 (2.73-4.60)
25	pcv13 vs pcv10	Africa	2-3-4 months	DTPw-HBV-Hib-TT + OPV		23.17 (18.75-28.65)
26	pcv13 vs pcv10	Oceania	2-4-6 months	DTPa-HBV-Hib-TT/IPV/Rotavirus		12.47 (9.76-15.94)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	+	1.00 (0.78-1.28)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	1.18 (0.97-1.45)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		10.77 (7.74-14.96)
					0.0 0.5 1.0 1.5 2.0 2.5	
				1	favours vac2 GMR(lgG) favours vac1	


GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 16. Trial level geometric mean ratios for serotypes 19A at post-primary vaccination series.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 19A - post prime	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		16.30 (12.77-20.80)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)	14.23 (11.70-17.32)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		6.93 (5.81-8.26)
18	pcv13 vs pcv10	Oceania	1-2-3 months	DTPw-HBV-Hib-TT + OPV		4.78 (3.78-6.04)
25	pcv13 vs pcv10	Africa	2-3-4 months	DTPw-HBV-Hib-TT + OPV		22.91 (17.79-29.50)
26	pcv13 vs pcv10	Oceania	2-4-6 months	DTPa-HBV-Hib-TT/IPV/Rotavirus		3.59 (2.78-4.65)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	1.30 (0.99-1.71)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	—■ →	2.50 (1.90-3.29)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		11.04 (8.23-14.80)
					0.0 0.5 1.0 1.5 2.0 2.5	
				f	favours vac2 GMR(lgG) favours vac1	

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 17. Trial level geometric mean ratios for serotypes 4 at pre-booster.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 18. Trial level geometric mean ratios for serotypes 6B at pre-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 6B - prior booster	GMR (95%CI)	
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV		0.55 (0.32-0.95)	
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV		1.01 (0.59-1.72)	
3	pcv7 vs pcv10	Europe	2-3-4 months	NA		0.84 (0.56-1.25)	
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	0.41 (0.33-0.51)	
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	0.59 (0.48-0.72)	
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-IPV + MenC	-	0.67 (0.52-0.85)	
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	-8	0.57 (0.44-0.74)	
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT) =	0.38 (0.31-0.46)	
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV	•	0.39 (0.33-0.45)	
18	pcv13 vs pcv10	Oceania	1-2-3 months	Measles, PPV	-	0.78 (0.62-0.99)	
27	pcv13 vs pcv10	Africa	6 weeks	NA	•	0.23 (0.18-0.31)	
27	pcv13 vs pcv10	Africa	14 weeks	NA	•	0.18 (0.13-0.24)	
27	pcv13 vs pcv10	Africa	6-14 weeks	NA	a -	0.25 (0.18-0.35)	
13	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-Hib-TT/IPV	-	0.92 (0.76-1.12)	
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	-	0.92 (0.79-1.07)	
19	pcv13 vs pcv7	Europe	2-4 months	Hib-MenC-TT	-	1.35 (0.86-2.12)	
22	pcv13 vs pcv7	North America	2-4-6 months	MMRV, Hib, HAV	-	0.77 (0.64-0.91)	
					0.0 0.5 1.0 1.5 2.0 2.5		
	favours vac2 GMR(lgG) favours vac1						


GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 19. Trial level geometric mean ratios for serotypes 9V at pre-booster.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 20. Trial level geometric mean ratios for serotypes 14 at pre-booster.



GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 21. Trial level geometric mean ratios for serotypes 18C at pre-booster.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 22. Trial level geometric mean ratios for serotypes 19F at pre-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 19F - prior booster	GMR (95%CI)	
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV	■-	0.11 (0.07-0.19)	
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV	-	0.32 (0.19-0.56)	
3	pcv7 vs pcv10	Europe	2-3-4 months	NA	-	0.43 (0.26-0.71)	
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV		0.35 (0.28-0.45)	
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	a -	0.47 (0.38-0.59)	
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-IPV + MenC		0.25 (0.19-0.33)	
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	-	0.49 (0.37-0.65)	
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT) -	0.45 (0.37-0.54)	
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV	•	0.55 (0.48-0.62)	
18	pcv13 vs pcv10	Oceania	1-2-3 months	Measles, PPV	-	0.75 (0.60-0.95)	
27	pcv13 vs pcv10	Africa	6 weeks	NA	-	1.10 (0.74-1.63)	
27	pcv13 vs pcv10	Africa	14 weeks	NA	-= -	0.88 (0.64-1.21)	
27	pcv13 vs pcv10	Africa	6-14 weeks	NA		0.83 (0.57-1.22)	
13	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-Hib-TT/IPV	-	0.92 (0.71-1.19)	
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	 = -	1.14 (0.96-1.35)	
19	pcv13 vs pcv7	Europe	2-4 months	Hib-MenC-TT	-	1.33 (0.80-2.23)	
22	pcv13 vs pcv7	North America	2-4-6 months	MMRV, Hib, HAV	-	1.11 (0.95-1.31)	
					 		
					0.0 0.5 1.0 1.5 2.0 2.5		
	favours vac2 GMR(lgG) favours vac1						

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 23. Trial level geometric mean ratios for serotypes 23F at pre-booster.



GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 24. Trial level geometric mean ratios for serotypes 1 at pre-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 1 - prior booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		1.81 (1.48-2.21)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)) 	1.70 (1.48-1.96)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		1.96 (1.71-2.25)
18	pcv13 vs pcv10	Oceania	1-2-3 months	Measles, PPV		1.44 (1.16-1.77)
27	pcv13 vs pcv10	Africa	6 weeks	NA	-	0.69 (0.48-0.99)
27	pcv13 vs pcv10	Africa	14 weeks	NA	-	0.89 (0.67-1.20)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA	-	1.30 (0.98-1.72)
					0.0 0.5 1.0 1.5 2.0 2.5	
				f	favours vac2 GMR(lgG) favours vac	1

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 25. Trial level geometric mean ratios for serotypes 5 at pre-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 5 - pri	or booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		_=	1.51 (1.22-1.87)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT))	_■	1.62 (1.40-1.87)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		-	1.58 (1.40-1.79)
18	pcv13 vs pcv10	Oceania	1-2-3 months	Measles, PPV		-■	1.26 (1.04-1.53)
27	pcv13 vs pcv10	Africa	6 weeks	NA	-		0.61 (0.43-0.87)
27	pcv13 vs pcv10	Africa	14 weeks	NA	-	i ■ 	1.32 (0.95-1.84)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA	-	 	1.23 (0.90-1.66)
					0.0 0.5 1	.0 1.5 2.0 2.5	
				f	avours vac2 GMR	(lgG) favours vac1	

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 26. Trial level geometric mean ratios for serotypes 7F at pre-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 7F - pr	rior booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		_ 	1.39 (1.15-1.68)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)	 - = -	1.30 (1.14-1.50)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		-	1.29 (1.13-1.47)
18	pcv13 vs pcv10	Oceania	1-2-3 months	Measles, PPV			1.35 (1.10-1.65)
27	pcv13 vs pcv10	Africa	6 weeks	NA	-		0.57 (0.40-0.80)
27	pcv13 vs pcv10	Africa	14 weeks	NA	_	-	1.10 (0.79-1.53)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA	-	 	1.18 (0.85-1.65)
					0.0 0.5 1	.0 1.5 2.0 2.5	
				f	avours vac2 GMR	(lgG) favours vac1	


GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 27. Trial level geometric mean ratios for serotypes 3 at pre-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 3 - prior booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		6.02 (4.68-7.74)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT))	4.13 (3.32-5.14)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV	→	3.25 (2.87-3.69)
18	pcv13 vs pcv10	Oceania	1-2-3 months	Measles, PPV		0.85 (0.64-1.14)
27	pcv13 vs pcv10	Africa	6 weeks	NA		2.00 (1.44-2.78)
27	pcv13 vs pcv10	Africa	14 weeks	NA	=	2.40 (1.71-3.37)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA		3.00 (2.06-4.36)
					- - - - - - - - - -	
					0.0 0.5 1.0 1.5 2.0 2.5	
				f	avours vac2 GMR(lgG) favours vac1	


GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 28. Trial level geometric mean ratios for serotypes 6A at pre-booster.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 29. Trial level geometric mean ratios for serotypes 19A at pre-booster.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 30. Trial level geometric mean ratios for serotypes 4 at post-booster.



GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 31. Trial level geometric mean ratios for serotypes 6B at post-booster.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 32. Trial level geometric mean ratios for serotypes 9V at post-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 9V - post booste	er GMR (95%CI)
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV	— = —	1.37 (1.03-1.83)
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV		
2	pcv7 vs pcv10	Asia	2-4-6 months	Hib-TT		— ■ 2.53 (2.12-3.01)
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	1.47 (1.28-1.68)
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	1.05 (0.92-1.20)
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-IPV + MenC		- 1.91 (1.63-2.24)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	- =	1.26 (1.04-1.52)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)	ļ 	1.57 (1.37-1.80)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV	-	1.57 (1.36-1.80)
27	pcv13 vs pcv10	Africa	6 weeks	NA	ļ —	1.47 (1.11-1.95)
27	pcv13 vs pcv10	Africa	14 weeks	NA	_■	1.53 (1.21-1.94)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA	├-■	1.33 (1.00-1.78)
10	pcv13 vs pcv7	Asia	6-10-14 weeks	NA	-=-	0.91 (0.77-1.07)
11	pcv13 vs pcv7	Asia	2-4-6 months	NA	=	0.94 (0.87-1.02)
12	pcv13 vs pcv7	Europe	3–5 months	DTPa-HBV-Hib-TT/IPV	-	0.73 (0.64-0.84)
13	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-Hib-TT/IPV	-	0.79 (0.68-0.92)
14	pcv13 vs pcv7	Asia	2-4-6 months	NA	- ■-¦	0.83 (0.65-1.06)
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	-	0.83 (0.73-0.94)
16	pcv13 vs pcv7	Asia	2-4-6 months	NA	-	0.99 (0.79-1.23)
17	pcv13 vs pcv7	North America	2-4-6 months	MMR	+	0.99 (0.88-1.11)
19	pcv13 vs pcv7	Europe	2-4 months	Hib-MenC-TT		0.78 (0.52-1.16)
20	pcv13 vs pcv7	Asia	enr 3-6 m, 4-8 w int	DTPa	-	0.81 (0.67-0.97)
21	pcv13 vs pcv7	South America	2-4-6 months	DTwP-Hib, OPV	 	1.12 (0.94-1.34)
22	pcv13 vs pcv7	North America	2-4-6 months	MMRV, Hib, HAV	-	0.72 (0.62-0.84)
23	pcv13 vs pcv7	Asia	3-4-5 months	NA	=-	0.80 (0.71-0.90)
					0.0 0.5 1.0 1.5 2.0	2.5
				fa	avours vac2 GMR(lgG) fa	vours vac1


GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 33. Trial level geometric mean ratios for serotypes 14 at post-booster.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 34. Trial level geometric mean ratios for serotypes 18C at post-booster.




GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 35. Trial level geometric mean ratios for serotypes 19F at post-booster.



GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 36. Trial level geometric mean ratios for serotypes 23F at post-booster.



GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 37. Trial level geometric mean ratios for serotypes 1 at post-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 1 - pos	st booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV			1.55 (1.28-1.89)
5	pcv13 vs pcv10	Europe	2–3–4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)		1.74 (1.51-2.00)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		- -	1.73 (1.48-2.03)
27	pcv13 vs pcv10	Africa	6 weeks	NA		—■	1.86 (1.35-2.56)
27	pcv13 vs pcv10	Africa	14 weeks	NA			2.32 (1.74-3.09)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA	-	•	1.25 (0.93-1.68)
				1	0.0 0.5 1.	0 1.5 2.0 2.5 (lgG) favours vac1	

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 38. Trial level geometric mean ratios for serotypes 5 at post-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 5 - po	st booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV			2.19 (1.80-2.68)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT))		2.30 (1.99-2.65)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		- ■	2.52 (2.21-2.88)
27	pcv13 vs pcv10	Africa	6 weeks	NA	_		1.19 (0.84-1.68)
27	pcv13 vs pcv10	Africa	14 weeks	NA			1.38 (1.05-1.83)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA			1.63 (1.24-2.15)
					0.0 0.5 1	0 1.5 2.0 2.5	
				_	o OME	//=0)	

favours vac2 GMR(lgG) favours vac1

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 39. Trial level geometric mean ratios for serotypes 7F at post-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 7F - po	ost booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		- ■	1.57 (1.33-1.85)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT))		1.46 (1.29-1.66)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		-=	1.80 (1.57-2.05)
27	pcv13 vs pcv10	Africa	6 weeks	NA			1.78 (1.39-2.28)
27	pcv13 vs pcv10	Africa	14 weeks	NA		-■	1.34 (1.09-1.65)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA		—■—	2.00 (1.58-2.53)
						0 1.5 2.0 2.5	
				T	avours vac2 GMR	(lgG) favours vac1	

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP - diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP - diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT -Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV - Oral polio vaccine; MenC - Meningococcal C vaccine; TT - tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 40. Trial level geometric mean ratios for serotypes 3 at post-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 3 - post booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		28.12 (21.95-36.03)
5	pcv13 vs pcv10	Europe	2–3–4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT))	22.16 (17.76-27.66)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		7.16 (6.14-8.36)
27	pcv13 vs pcv10	Africa	6 weeks	NA		8.34 (6.00-11.59)
27	pcv13 vs pcv10	Africa	14 weeks	NA		5.00 (3.78-6.62)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA		7.34 (5.45-9.89)
					0.0 0.5 1.0 1.5 2.0 2.5	
				_	0 OMP/(-O)	

favours vac2 GMR(lgG) favours vac1

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 41. Trial level geometric mean ratios for serotypes 6A at post-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 6A - post booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		8.07 (6.13-10.62)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)		10.30 (8.41-12.61)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		6.33 (5.21-7.70)
27	pcv13 vs pcv10	Africa	6 weeks	NA		23.61 (16.53-33.72)
27	pcv13 vs pcv10	Africa	14 weeks	NA		21.04 (14.86-29.78)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA		24.32 (16.95-34.90)
					<u> </u>	
					0.0 0.5 1.0 1.5 2.0 2.5	
				f	avours vac2 GMR(lgG) favours vac1	

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 42. Trial level geometric mean ratios for serotypes 19A at post-booster.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	Concomitant vaccines	Serotype 19A - post booster	GMR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		6.65 (5.07-8.73)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT))	6.07 (4.87-7.57)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		5.22 (4.39-6.20)
27	pcv13 vs pcv10	Africa	6 weeks	NA		14.16 (9.52-21.06)
27	pcv13 vs pcv10	Africa	14 weeks	NA		12.19 (8.23-18.05)
27	pcv13 vs pcv10	Africa	6-14 weeks	NA		11.40 (7.80-16.66)
					<u> </u>	
					0.0 0.5 1.0 1.5 2.0 2.5	
				f	avours vac2 GMR(lgG) favours vac1	

GMR: Geometric mean ratio; pcv: Pneumococcal conjugate vaccine; DTaP - diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP - diphtheria and tetanus toxoids, and whole-cell pertussis vaccine: Hib-TT -Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV - Oral polio vaccine; MenC - Meningococcal C vaccine; TT - tetanus toxoid conjugate; NA: not applicable; enr 3-6 m, 4-8 w int: enrolment at 3-6 months of age, and at 4-8 weeks interval of a 3 doses primary vaccines in total.

Supplementary Figure 43. Sensitivity analysis on geometric mean ratios comparing PCV13 vs PCV10, PCV7 vs PCV10, and PCV13 vs PCV7 at a) post-primary vaccination series, b) pre-boost, and c) post-boost by including studies providing data for all three time points.

	Serotype	No. cohorts	Direct Evidence (%)	GMR at 1 month after prime (SA) PCV13 vs PCV10	GMR (95% CI) PCV13 vs PCV10	GMR (95% CI) PCV7 vs PCV10	GMR (95% CI) PCV13 vs PCV7
	4	14	62	+	1.01 (0.83, 1.23)	1.49 (1.23, 1.81)	0.68 (0.54, 0.85)
	6B	14	76	-	0.80 (0.66, 0.97)	1.36 (1.12, 1.66)	0.59 (0.47, 0.73)
	9V	14	63	-	1.15 (0.95, 1.41)	1.63 (1.34, 1.99)	0.71 (0.56, 0.89)
PCV7	14	14	64	+	1.01 (0.85, 1.21)	1.32 (1.11, 1.57)	0.77 (0.63, 0.94)
	18C	14	62	-	1.18 (0.87, 1.61)	1.03 (0.75, 1.42)	1.15 (0.80, 1.65)
	19F	14	65	_	0.93 (0.63, 1.37)	0.94 (0.63, 1.42)	0.99 (0.62, 1.56)
	23F	14	68	-	1.38 (1.09, 1.74)	1.86 (1.46, 2.37)	0.74 (0.56, 0.97)
	1	6	100	_	1.11 (0.72, 1.70)	0.02 (0.02, 0.03)	58.61 (42.73, 80.39)
PCV10) 5	6	100		0.92 (0.60, 1.40)	0.03 (0.01, 0.05)	19.07 (9.66, 37.67)
	7F	6	100	-	1.32 (1.13, 1.55)	0.02 (0.01, 0.02)	66.25 (52.26, 84.00)
	3	6	100		1 5.28 (7.54, 30.98)	0.92 (0.29, 2.85)	16.81 (9.03, 31.31)
PCV1	3 6A	6	100		5.41 (1.94, 15.06)	1.01 (0.52, 1.96)	6.21 (4.39, 8.80)
	19A	6	100		6.23 (2.94, 13.18)	0.94 (0.52, 1.67)	2.75 (1.46, 5.21)
			0.1	1 10	100		
			favours P		favours PCV13		


	Serotype	No. cohorts	Direct Evidence (%)	GMR at Before booster (SA) PCV13 vs PCV10	GMR (95% CI) PCV13 vs PCV10	GMR (95% CI) PCV7 vs PCV10	GMR (95% CI) PCV13 vs PCV7
	4	17	69	-	0.66 (0.56, 0.78)	0.95 (0.80, 1.12)	0.70 (0.58, 0.84)
	6B	17	74	-	0.41 (0.32, 0.51)	0.53 (0.42, 0.68)	0.76 (0.58, 0.98)
	9V	17	68	-	0.74 (0.62, 0.89)	0.96 (0.80, 1.16)	0.77 (0.63, 0.95)
PCV7	14	17	65	•	1.26 (1.13, 1.40)	1.53 (1.37, 1.71)	0.82 (0.73, 0.92)
	18C	17	66	-	0.78 (0.67, 0.91)	0.77 (0.66, 0.90)	1.01 (0.85, 1.19)
	19F	17	79	-	0.57 (0.46, 0.70)	0.38 (0.30, 0.48)	1.48 (1.16, 1.88)
	23F	17	73	-	0.64 (0.54, 0.77)	0.81 (0.67, 0.97)	0.80 (0.65, 0.97)
	1	7	100	-	1.36 (1.09, 1.71)	0.13 (0.10, 0.16)	12.48 (9.83, 15.84)
PCV10	5	7	100	-	1.30 (1.09, 1.56)	0.18 (0.11, 0.29)	4.43 (2.56, 7.68)
	7F	7	100	•	1.18 (1.01, 1.38)	0.05 (0.04, 0.06)	20.43 (17.11, 24.39)
	3	7	100	-	2.70 (1.78, 4.09)	0.95 (0.51, 1.76)	2.90 (2.07, 4.06)
PCV13	6A	7	100	-	2.11 (1.50, 2.97)	0.75 (0.58, 0.96)	2.77 (2.16, 3.55)
	19A	7	100	+	2.23 (1.76, 2.82)	0.63 (0.46, 0.87)	1.50 (1.28, 1.76)
				i			
			0.1	1 10	100		
			favours PC	V10 GMR(lgG)	favours PCV13		

	Serotype	No. cohorts	Direct Evidence (%)	GMR at 1 month after booster (SA) PCV13 vs PCV10	GMR (95% CI) PCV13 vs PCV10	GMR (95% CI) PCV7 vs PCV10	GMR (95% CI) PCV13 vs PCV7	
	4	14	73	+	1.04 (0.93, 1.15)	1.38 (1.23, 1.54)	0.75 (0.67, 0.85)	
	6B	14	73	-	1.25 (1.01, 1.55)	1.63 (1.30, 2.04)	0.77 (0.60, 0.99)	
	9 V	14	72	-	1.40 (1.18, 1.67)	1.68 (1.40, 2.02)	0.83 (0.68, 1.02)	
PCV7	14	14	69	•	1.43 (1.22, 1.66)	1.72 (1.47, 2.00)	0.83 (0.70, 0.99)	
	18C	14	73	-	0.78 (0.66, 0.93)	0.89 (0.74, 1.07)	0.88 (0.72, 1.08)	
	19F	14	74	+	0.93 (0.74, 1.15)	0.56 (0.45, 0.70)	1.64 (1.27, 2.12)	
	23F	14	76	-	1.60 (1.33, 1.92)	2.22 (1.81, 2.71)	0.72 (0.58, 0.89)	
	1	6	100	•	1.71 (1.51, 1.93)	0.02 (0.01, 0.03)	125.80 (71.00, 222.91)	
PCV10) 5	6	100	-	1.87 (1.52, 2.30)	0.04 (0.02, 0.10)	25.12 (9.55, 66.10)	
	7F	6	100	•	1.63 (1.46, 1.82)	0.01 (0.01, 0.02)	115.07 (73.61, 179.87)	
	3	6	100		10.56 (6.03, 18.49)	0.76 (0.33, 1.78)	13.92 (12.19, 15.90)	
PCV13	6 A	6	100		13.40 (8.48, 21.16)	1.98 (1.38, 2.83)	4.48 (3.24, 6.21)	
	19A	6	100	-	8.36 (6.08, 11.49)	0.65 (0.36, 1.16)	2.46 (2.23, 2.73)	
			_					
			0.1	1 10	100			
favours PCV10 GMR(IgG) favours PCV13								

c)


GMR: Geometric mean ratio; PCV: Pneumococcal conjugate vaccine. Each line in the figure shows the output from a network meta-analyses (PCV7 serotypes) or direct meta-analyses (PCV13 but non-PCV7 serotypes). Blue boxes and blue lines show the point estimates and confidence intervals for geometric mean ratios comparing PCV13 vs PCV10. Points to the right of the vertical line are those with higher antibody responses in the PCV13 arm of the study, and points to the left are those with higher antibody responses in the PCV10 arm. The direct evidence column shows the percentage of evidence from studies directly comparing PCV13 vs PCV10 that contributes to the estimates presented in the figure in blue (PCV13 vs PCV10). GMR of PCV13 vs PCV10 for PCV10 and PCV13 serotypes are from a meta-analysis of only head-to-head studies of PCV13 vs PCV10.

Supplementary Figure 44. Direct and indirect evidence on relative risk comparing PCV13 vs PCV10 for serotypes in PCV7 (4, 6B, 9V, 14, 18C, 19F and 23F)



RR: Relative risk; PCV: Pneumococcal conjugate vaccine. Each line in the figure shows the output from a network meta-analyses. Dark grey diamonds and lines show the point estimates and confidence intervals relative risks from studies directly comparing PCV13 vs PCV10. Light grey diamonds and lines show the point estimates and confidence intervals for relative risks from studies comparing PCV13 vs PCV10 through PCV7. Black boxes and lines show the point estimates and confidence intervals incorporating both direct and indirect evidence.

Supplementary Figure 45. Trial level relative risk for serotype 4.



RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.

Supplementary Figure 46. Trial level relative risk for serotype 6B.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	co-adm vaccines	Serotype 6B		RR (95%CI)
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV		i - !	0.58 (0.28-1.22)
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV		<u> </u>	0.88 (0.45-1.72)
3	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		i 	0.50 (0.28-0.87)
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV		i I I	0.27 (0.16-0.43)
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	 	0.30 (0.21-0.43)
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-TT/IPV + MenC		 	0.41 (0.24-0.69)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	-■-	 	0.55 (0.40-0.76)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	! ! !	0.80 (0.70-0.92)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		<u> </u> -	0.85 (0.57-1.27)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	! ! !	0.68 (0.54-0.86)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)	-	; ! !	0.32 (0.23-0.45)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV	-	i 	0.83 (0.73-0.94)
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		¦- = -	1.37 (1.13-1.67)
19	pcv13 vs pcv7	Europe	2-4 months	DTaP-IPV-Hib/MenC		- ■-	2.02 (1.35-3.01)
22	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV			1.79 (1.09-2.94)
						 	
					0.0625 0.25	1 2 4	
					Risk lower in vac1	RR Risk lov	er in vac2


RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.

Supplementary Figure 47. Trial level relative risk for serotype 9V.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	co-adm vaccines	Serotype 9V	RR (95%CI)
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV		0.24 (0.03-1.75)
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV		0.28 (0.04-2.10)
3	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		0.47 (0.13-1.72)
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV		0.25 (0.11-0.58)
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV		0.56 (0.33-0.95)
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-TT/IPV + MenC		0.48 (0.24-0.95)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	— ■	0.62 (0.26-1.44)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	+	1.00 (0.76-1.32)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		1.06 (0.50-2.26)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		0.51 (0.32-0.80)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)		0.29 (0.14-0.61)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		0.42 (0.20-0.90)
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		0.77 (0.34-1.73)
19	pcv13 vs pcv7	Europe	2-4 months	DTaP-IPV-Hib/MenC		2.30 (0.25-21.18)
22	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV		1.28 (0.62-2.63)
					0.0625 0.25 1 2 4	
					Risk lower in vac1 RR Risk lo	wer in vac2

RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.

Supplementary Figure 48. Trial level relative risk for serotype 14.



RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.

Supplementary Figure 49. Trial level relative risk for serotype 18C.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	co-adm vaccines	Serotype 18C	RR (95%CI)
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV	- ■ →	0.50 (0.06-4.04)
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV		2.30 (0.53-9.90)
3	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		0.56 (0.05-5.98)
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV		0.20 (0.07-0.55)
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV		0.26 (0.08-0.85)
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-TT/IPV + MenC		0.28 (0.07-1.18)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		0.67 (0.26-1.71)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.94 (0.65-1.36)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		0.42 (0.17-1.03)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.86 (0.52-1.44)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)		0.28 (0.12-0.64)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		0.20 (0.07-0.56)
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		0.60 (0.15-2.50)
19	pcv13 vs pcv7	Europe	2-4 months	DTaP-IPV-Hib/MenC		0.25 (0.01-5.86)
22	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV		1.91 (0.48-7.53)
					0.0625 0.25 1 2 4	
					Risk lower in vac1 RR Risk lo	wer in vac2

RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.

Supplementary Figure 50. Trial level relative risk for serotype 4.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	co-adm vaccines	Serotype 19F	RR (95%CI)
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV		1.50 (0.39-5.76)
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV	 •	1.95 (0.80-4.74)
3	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		0.55 (0.18-1.71)
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV		0.56 (0.32-0.96)
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	- =	0.78 (0.51-1.21)
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-TT/IPV + MenC	 -	1.62 (0.85-3.10)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	— -	1.27 (0.58-2.80)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		0.47 (0.31-0.70)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	_ _	0.78 (0.39-1.55)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.89 (0.51-1.55)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)		0.56 (0.28-1.12)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		0.66 (0.35-1.25)
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	 	1.35 (0.78-2.35)
19	pcv13 vs pcv7	Europe	2-4 months	DTaP-IPV-Hib/MenC		2.50 (0.74-8.43)
22	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV	-	1.59 (0.82-3.08)
					0.0625 0.25 1 2 4	
				Ri	sk lower in vac1 RR Risk lo	wer in vac2

RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.

Supplementary Figure 51. Trial level relative risk for serotype 23F.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	co-adm vaccines	Serotype 23F	RR (95%CI)
1	pcv7 vs pcv10	Asia	6-10-24 weeks	DTPw-HBV-Hib-TT + OPV		0.48 (0.20-1.15)
1	pcv7 vs pcv10	Europe	2-4-6 months	DTPw-HBV-Hib-TT + IPV		2.30 (1.03-5.11)
3	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		0.18 (0.06-0.58)
7	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV		0.24 (0.14-0.43)
8	pcv7 vs pcv10	Europe	2-3-4 months	DTPa-(HBV)-Hib-TT/IPV	-	0.35 (0.23-0.54)
9	pcv7 vs pcv10	Europe	2-4-6 months	DTPa-(HBV)-Hib-TT/IPV + MenC		0.47 (0.23-0.97)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	- ■	0.21 (0.11-0.38)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	0.85 (0.70-1.04)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		0.42 (0.20-0.85)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	+	0.95 (0.72-1.25)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)	-	0.29 (0.18-0.45)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV	-	0.39 (0.28-0.56)
15	pcv13 vs pcv7	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	— -	0.69 (0.38-1.24)
19	pcv13 vs pcv7	Europe	2-4 months	DTaP-IPV-Hib/MenC	 	2.25 (0.90-5.62)
22	pcv13 vs pcv7	North America	2-4-6 months	DTPa-HBV-Hib-TT/IPV	-	1.78 (0.72-4.37)
					0.0625 0.25 1 2 4	
					Risk lower in vac1 RR Risk le	ower in vac2

RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.

Supplementary Figure 52. Trial level relative risk for serotype 1.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	co-adm vaccines	Serotype 1	RR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		2.46 (0.49-12.48)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		1.42 (0.73-2.74)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	1.53 (0.63-3.73)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	1.56 (0.87-2.83)
5	pcv13 vs pcv10	Europe	2–3–4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)		0.48 (0.09-2.57)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		0.32 (0.11-0.96)
				0	.0625 0.25 1 2 4	

RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.

RR Risk lower in vac2

Risk lower in vac1

Supplementary Figure 53. Trial level relative risk for serotype 5.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	co-adm vaccines	Serotype 5		RR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV	<u> </u>	>	2.91 (0.81-10.52)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT//PV/Rotavirus		\rightarrow	4.38 (2.19-8.74)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		■→	1.95 (0.37-10.31)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	_	-■->	2.38 (1.04-5.44)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)			2.83 (0.93-8.63)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV			0.47 (0.26-0.84)
					0.0625 0.25 1	2 4	
				Ri	sk lower in vac1 RR	Risk lowe	er in vac2

RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.


Supplementary Figure 54. Trial level relative risk for serotype 7F.

ID	Comparison vac1 vs vac2	Continent	Schedule-prime	co-adm vaccines	Serotype 7F	RR (95%CI)
4	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV		1.29 (0.56-2.97)
27	pcv13 vs pcv10	Africa	14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus	-	1.00 (0.73-1.36)
27	pcv13 vs pcv10	Africa	6-14 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		0.49 (0.13-1.88)
27	pcv13 vs pcv10	Africa	6 weeks	DTPa-HBV-Hib-TT/IPV/Rotavirus		0.83 (0.59-1.16)
5	pcv13 vs pcv10	Europe	2-3-4 months	DTPa-HBV-Hib-TT/IPV + (MenC-TT)		0.58 (0.31-1.09)
6	pcv13 vs pcv10	Asia	2-4 months	DTPa-HBV-Hib-TT/IPV		0.77 (0.33-1.80)
				0	.0625 0.25 1 2 4	

Risk lower in vac1 RR Risk lower in vac2

RR: relative risk; pcv: Pneumococcal conjugate vaccine; DTaP – diphtheria and tetanus toxoids, and acellular pertussis vaccine; DTwP – diphtheria and tetanus toxoids, and whole-cell pertussis vaccine; Hib-TT – Haemophilus influenzae type b vaccine (tetanus toxoid conjugate); HB – Hepatitis B vaccine; IPV – Inactivated polio vaccine; OPV – Oral polio vaccine; MenC – Meningococcal C vaccine; TT – tetanus toxoid conjugate; NA: not applicable.

Supplementary Figure 55. Study level association between geometric mean ratio and relative risk for each serotype in PCV7



RR: relative risk; GMR: Geometric mean ratio; PCV: Pneumococcal conjugate vaccine. Each point shows results of a serotype specific head-to-head comparison between two vaccines from one study. Solid line shows the relationship between relative risk predicted from the crude model and geometric mean ratio. Dashed line shows the confidence intervals of predicted relative risk. Reference lines show geometric mean ratio equivalent to one (vertical) and relative risk equivalent to one (horizontal) which represent values associated with no difference between vaccines. Points sizes represent sample size of the trial. Each panel shows one PCV7 serotype (4, 6B, 9V, 14, 18C, 19F and 23F).